Oxford–AstraZeneca COVID-19 vaccine: need of a reasoned and effective vaccine campaign

OBJECTIVES: A strong COVID-19 vaccine campaign is needed to reach the herd immunity and reduce this pandemic infection. STUDY DESIGN: In the Foch Hospital, France, in February 2021, 451 healthcare workers were vaccinated by a first dose of AstraZeneca vaccine. METHODS: Adverse effects were reported...

Descripción completa

Detalles Bibliográficos
Autores principales: Vallée, A., Chan-Hew-Wai, A., Bonan, B., Lesprit, P., Parquin, F., Catherinot, É., Choucair, J., Billard, D., Amiel-Taieb, C., Camps, È., Cerf, C., Zucman, D., Fourn, E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Royal Society for Public Health. Published by Elsevier Ltd. 2021
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8169320/
https://www.ncbi.nlm.nih.gov/pubmed/34198072
http://dx.doi.org/10.1016/j.puhe.2021.05.030
Descripción
Sumario:OBJECTIVES: A strong COVID-19 vaccine campaign is needed to reach the herd immunity and reduce this pandemic infection. STUDY DESIGN: In the Foch Hospital, France, in February 2021, 451 healthcare workers were vaccinated by a first dose of AstraZeneca vaccine. METHODS: Adverse effects were reported to our pharmaco-vigilance circuit, by an online and anonymous questionnaire following the first weeks of the vaccinal campaign to healthcare workers. RESULTS: Two hundred seventy-four (60.8%) of them reported multiple adverse effects. Main adverse effects reported were feverish state/chills (65.7%), fatigue/physical discomfort (62.4%), arthralgia/muscle pain (61.0%) and fever (44.5%). CONCLUSIONS: On March 2021 many European countries suspended AstraZeneca vaccine for one week due to safety uncertainty. Thus, confidence in its efficacy is undermined. However, the benefit/risk balance is clearly in favor of vaccination.

Ejemplares similares